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Non-randomised studies of the 
efects of interventions are critical to 
many areas of healthcare evaluation, 
but their results may be biased. It is 
therefore important to understand 
and appraise their strengths and 
weaknesses. We developed ROBINS-I 
(“Risk Of Bias In Non-randomised 
Studies - of Interventions”), a new 
tool for evaluating risk of bias in 
estimates of the comparative 
efectiveness (harm or beneit) of 
interventions from studies that did 
not use randomisation to allocate 
units (individuals or clusters of 
individuals) to comparison groups. 
The tool will be particularly useful to 
those undertaking systematic 
reviews that include non-randomised 
studies.
Non-randomised studies of the efects of interventions 
(NRSI) are critical to many areas of healthcare evalua-
tion. Designs of NRSI that can be used to evaluate the 
efects of interventions include observational studies 
such as cohort studies and case-control studies in 
which intervention groups are allocated during the 
course of usual treatment decisions, and quasi-ran-
domised studies in which the method of allocation 
falls short of full randomisation. Non-randomised 
studies can provide evidence additional to that avail-
able from randomised trials about long term out-
comes, rare events, adverse efects and populations 
that are typical of real world practice.1 2  The availabil-
ity of linked databases and compilations of electronic 
health records has enabled NRSI to be conducted in 
large representative population cohorts.3 For many 
types of organisational or public health interventions, 
NRSI are the main source of evidence about the likely 
impact of the intervention because randomised trials 
are diicult or impossible to conduct on an area-wide 
basis. Therefore systematic reviews addressing the 
efects of health related interventions often include 
NRSI. It is essential that methods are available to eval-
uate these studies, so that clinical, policy, and individ-
ual decisions are transparent and based on a full 
understanding of the strengths and weaknesses of the 
evidence.
Many tools to assess the methodological quality of 
observational studies in the context of a systematic 
review have been proposed.4 5  The Newcastle-Ottawa6 
and Downs-Black7  tools have been two of the most pop-
ular: both were on a shortlist of methodologically 
sound tools,5  but each includes items relating to exter-
nal as well as internal validity and a lack of comprehen-
sive manuals means that instructions may be 
interpreted diferently by diferent users.5
In the past decade, major developments have been 
made in tools to assess study validity. A shift in focus 
from methodological quality to risk of bias has been 
accompanied by a move from checklists and numeric 
scores towards domain-based assessments in which 
diferent types of bias are considered in turn. Examples 
are the Cochrane Risk of Bias tool for randomised 
 trials,8  the QUADAS 2 tool for diagnostic test accuracy 
studies,9  and the ROBIS tool for systematic reviews.10 
However, there is no satisfactory domain-based assess-
ment tool for NRSI.4
In this paper we describe the development of 
ROBINS-I (“Risk Of Bias In Non-randomised 
 Studies  - of Interventions”), which is concerned 
with evaluating risk of bias in estimates of the 
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 effectiveness or safety (benefit or harm) of an inter-
vention from studies that did not use randomisation 
to allocate interventions.
Development of a new tool
We developed the tool over three years, largely by 
expert consensus, and following the seven principles 
we previously described for assessing risk of bias in 
clinical trials.8  A core group coordinated develop-
ment of the tool, including recruitment of collabora-
tors, preparation and revision of documents, and 
administrative support. An initial scoping meeting in 
October 2011 was followed by a survey of Cochrane 
Review Groups in March 2012 to gather information 
about the methods they were using to assess risk of 
bias in NRSI. A meeting in April 2012 identiied the 
relevant bias domains and established working 
groups focusing on each of these. We agreed at this 
stage to use the approach previously adopted in the 
QUADAS-2 tool, in which answers to “signalling ques-
tions” help reviewers judge the risk of bias within 
each domain.9 We distributed brieing documents to 
working groups in June 2012, specifying consider-
ations for how signalling questions should be formu-
lated and how answers to these would lead to a risk of 
bias judgement. We also identiied methodological 
issues that would underpin the new tool: these are 
described below.
After collation and harmonisation by the core group 
of the working groups’ contributions, all collaborators 
considered draft signalling questions and agreed on the 
main features of the new tool during a two-day face-to-
face meeting in March 2013. A preliminary version of 
the tool was piloted within the working groups between 
September 2013 and March 2014, using NRSI in several 
review topic areas. Substantial revisions, based on 
results of the piloting, were agreed by leads of working 
groups in June 2014. Further piloting took place, along 
with a series of telephone interviews with people using 
the tool for the irst time that explored whether they 
were interpreting the tool and the guidance as intended. 
We posted version 1.0.0, along with detailed guidance, 
at www.riskofbias.info in September 2014. We 
explained the tool during a three-day workshop involv-
ing members of Cochrane Review Groups in December 
2014, and applied it in small groups to six papers report-
ing NRSI. Further modiications to the tool, particularly 
regarding wording, were based on feedback from this 
event and from subsequent training events conducted 
during 2015.
Methodological issues in assessing risk of bias in 
non-randomised studies
The target trial
Evaluations of risk of bias in the results of NRSI are 
facilitated by considering each NRSI as an attempt to 
emulate (mimic) a “target” trial. This is the hypotheti-
cal pragmatic randomised trial, conducted on the 
same participant group and without features putting it 
at risk of bias, whose results would answer the ques-
tion addressed by the NRSI.11 12 Such a “target” trial 
need not be feasible or ethical: for example, it could 
compare individuals who were and were not assigned 
to start smoking. Description of the target trial for the 
NRSI being assessed includes details of the popula-
tion, experimental intervention, comparator, and out-
comes of interest. Correspondingly, we deine bias as a 
systematic diference between the results of the NRSI 
and the results expected from the target trial. Such 
bias is distinct from issues of generalisability (applica-
bility or transportability) to types of individuals who 
were not included in the study.
The efect of interest
In the target trial, the efect of interest will typically be 
that of either:
1. Assignment to intervention at baseline (start of follow 
up), regardless of the extent to which the intervention 
was received during the follow-up (sometimes 
referred to as the “intention-to-treat” efect)
2. Starting and adhering to the intervention as indi-
cated in the trial protocol (sometimes referred to as 
the “per-protocol” efect).
For example, in a trial of cancer screening, our interest 
might be in the efect of either sending an invitation to 
attend screening or of responding to the invitation and 
undergoing screening.
Analogues of these efects can be deined for NRSI. 
For example, the intention-to-treat efect in a study 
comparing aspirin with no aspirin can be approximated 
by the efect of being prescribed aspirin or (if using dis-
pensing rather than prescription data) the efect of 
starting aspirin (this corresponds to the intention-to-
treat efect in a trial in which participants assigned to 
an intervention always start that intervention). Alterna-
tively, we might be interested in the efect of starting 
and adhering to aspirin.
The type of efect of interest inluences assessments 
of risk of bias related to deviations from intervention. 
When the efect of interest is that of assignment to (or 
starting) intervention, risk of bias assessments gener-
ally need not be concerned with post-baseline devia-
tions from interventions.13 By contrast, unbiased 
estimation of the efect of starting and adhering to inter-
vention requires consideration of both adherence and 
diferences in additional interventions (“co-interven-
tions”) between intervention groups.
Domains of bias
We achieved consensus on seven domains through 
which bias might be introduced into a NRSI (see table 1 
and appendix in supplementary data). The irst two 
domains, covering confounding and selection of partici-
pants into the study, address issues before the start of the 
interventions that are to be compared (“baseline”). The 
third domain addresses classiication of the interven-
tions themselves. The other four domains address issues 
after the start of interventions: biases due to deviations 
from intended interventions, missing data, measure-
ment of outcomes, and selection of the reported result.
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For the irst three domains, risk of bias assessments 
for NRSI are mainly distinct from assessments of ran-
domised trials because randomisation, if properly 
implemented, protects against biases that arise before 
the start of intervention. However, randomisation does 
not protect against biases that arise after the start of 
intervention. Therefore, there is substantial overlap for 
the last four domains between bias assessments in 
NRSI and randomised trials.
Variation in terminology proved a challenge to devel-
opment of ROBINS-I. The same terms are sometimes 
used to refer to diferent types of bias in randomised 
trials and NRSI literature,13  and diferent types of bias 
are often described by a host of diferent terms: those 
used within ROBINS-I are shown in the irst column of 
table 1.
The risk of bias tool, ROBINS-I
The full ROBINS-I tool is shown in tables A, B, and C in 
the supplementary data.
Planning the risk of bias assessment
It is very important that experts in both subject matter 
and epidemiological methods are included in any team 
evaluating a NRSI. The risk of bias assessment should 
begin with consideration of what problems might arise, 
in the context of the research question, in making a 
causal assessment of the efect of the intervention(s) of 
interest on the basis of NRSI. This will be based on 
experts’ knowledge of the literature: the team should 
also address whether conlicts of interest might afect 
experts’ judgements.
The research question is conceptualised by deining 
the population, experimental intervention, comparator, 
and outcomes of interest (supplementary table A, stage 
I). The comparator could be “no intervention,” “usual 
care,” or an alternative intervention. It is important 
to  consider in advance the confounding factors and 
co-interventions that have the potential to lead to bias. 
Relevant confounding domains are the prognostic fac-
tors that predict whether an individual receives one or 
the other intervention of interest. Relevant co-interven-
tions are those that individuals might receive with or 
after starting the intervention of interest and that are 
both related to the intervention received and prognostic 
for the outcome of interest. Both confounding domains 
and co-interventions are likely to be identiied through 
the expert knowledge of members of the review group 
and through initial (scoping) reviews of the literature. 
Discussions with health professionals who make 
 intervention decisions for the target patient or popula-
tion groups may also help in identiication of prognos-
tic factors that inluence treatment decisions.
Assessing a speciic study
The assessment of each NRSI included in the review 
involves following the six steps below (supplementary 
table A, stage II). Steps 3 to 6 should be repeated for 
each key outcome of interest:
1. Specify the research question through consideration 
of a target trial
2. Specify the outcome and result being assessed
3. For the speciied result, examine how the confound-
ers and co-interventions were addressed
4. Answer signalling questions for the seven bias 
domains
5. Formulate risk of bias judgements for each of the 
seven bias domains, informed by answers to the sig-
nalling questions
6. Formulate an overall judgement on risk of bias for the 
outcome and result being assessed.
Table 1 | Bias domains included in ROBINS-I
Domain Explanation
Pre-intervention Risk of bias assessment is mainly distinct from assessments of randomised trials
Bias due to 
confounding
Baseline confounding occurs when one or more prognostic variables (factors that predict the outcome of interest) also predicts the intervention 
received at baseline
ROBINS-I can also address time-varying confounding, which occurs when individuals switch between the interventions being compared and when 
post-baseline prognostic factors afect the intervention received ater baseline
Bias in selection of 
participants into the 
study
When exclusion of some eligible participants, or the initial follow-up time of some participants, or some outcome events is related to both 
intervention and outcome, there will be an association between interventions and outcome even if the efects of the interventions are identical
This form of selection bias is distinct from confounding—A speciic example is bias due to the inclusion of prevalent users, rather than new users, of 
an intervention
At intervention Risk of bias assessment is mainly distinct from assessments of randomised trials
Bias in classiication of 
interventions
Bias introduced by either diferential or non-diferential misclassiication of intervention status
Non-diferential misclassiication is unrelated to the outcome and will usually bias the estimated efect of intervention towards the null
Diferential misclassiication occurs when misclassiication of intervention status is related to the outcome or the risk of the outcome, and is likely to 
lead to bias
Post-intervention Risk of bias assessment has substantial overlap with assessments of randomised trials
Bias due to deviations 
from intended 
interventions
Bias that arises when there are systematic diferences between experimental intervention and comparator groups in the care provided, which 
represent a deviation from the intended intervention(s)
Assessment of bias in this domain will depend on the type of efect of interest (either the efect of assignment to intervention or the efect of starting 
and adhering to intervention).
Bias due to missing 
data
Bias that arises when later follow-up is missing for individuals initially included and followed (such as diferential loss to follow-up that is afected by 
prognostic factors); bias due to exclusion of individuals with missing information about intervention status or other variables such as confounders
Bias in measurement of 
outcomes
Bias introduced by either diferential or non-diferential errors in measurement of outcome data. Such bias can arise when outcome assessors are 
aware of intervention status, if diferent methods are used to assess outcomes in diferent intervention groups, or if measurement errors are related 
to intervention status or efects
Bias in selection of the 
reported result
Selective reporting of results in a way that depends on the indings and prevents the estimate from being included in a meta-analysis (or other 
synthesis)
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Examination of confounders and co-interventions 
involves determining whether the important confound-
ers and co-interventions were measured or adminis-
tered in the study at hand, and whether additional 
confounders and co-interventions were identiied. Sup-
plementary table A provides a structured approach to 
assessing the potential for bias due to confounding and 
co-interventions and includes the full tool with the sig-
nalling questions to be addressed within each bias 
domain.
The signalling questions are broadly factual in nature 
and aim to facilitate judgements about the risk of bias. 
The response options are: “Yes”; “Probably yes”; 
“ Probably no”; “No”; and “No information”. Some ques-
tions are answered only if the response to a previous 
question is “Yes” or “Probably yes” (or “No” or “Proba-
bly no”). Responses of “Yes” are intended to have similar 
implications to responses of “Probably yes” (and simi-
larly for “No” and “Probably no”), but allow for a dis-
tinction between something that is known and 
something that is likely to be the case. Free text should 
be used to provide support for each answer, using direct 
quotations from the text of the study where possible.
Responses to signalling questions provide the basis 
for domain-level judgements about risk of bias, which 
then provide the basis for an overall risk of bias judge-
ment for a particular outcome. The use of the word 
“judgement” to describe this process is important and 
relects the need for review authors to consider both the 
severity of the bias in a particular domain and the rela-
tive consequences of bias in diferent domains.
The categories for risk of bias judgements are “Low 
risk”, “Moderate risk”, “Serious risk” and “Critical risk” 
of bias. Importantly, “Low risk” corresponds to the risk 
of bias in a high quality randomised trial. Only excep-
tionally will an NRSI be assessed as at low risk of bias 
due to confounding. Criteria for reaching risk of bias 
judgements for the seven domains are provided in sup-
plementary tables B and C. If none of the answers to the 
signalling questions for a domain suggests a potential 
problem then risk of bias for the domain can be judged 
to be low. Otherwise, potential for bias exists. Review 
authors must then make a judgement on the extent to 
which the results of the study are at risk of bias. “Risk of 
bias” is to be interpreted as “risk of material bias”. That 
is, concerns should be expressed only about issues that 
are likely to afect the ability to draw valid conclusions 
from the study: a serious risk of a very small degree of 
bias should not be considered “Serious risk” of bias. The 
“No information” category should be used only when 
insuicient data are reported to permit a judgement.
The judgements within each domain carry forward to 
an overall risk of bias judgement for the outcome being 
assessed (across bias domains, that is), as summarised 
in table 2 (also saved as supplementary table D). The 
key to applying the tool is to make domain-level judge-
ments about risk of bias that have the same meaning 
across domains with respect to concern about the 
impact of bias on the trustworthiness of the result. If 
domain-level judgements are made consistently, then 
judging the overall risk of bias for a particular outcome 
is relatively straightforward. For instance, a “Serious 
risk” of bias in one domain means the efect estimate 
from the study is at serious risk of bias or worse, even if 
the risk of bias is judged to be lower in the other 
domains.
It would be highly desirable to know the magnitude 
and direction of any potential biases identiied, but this 
is considerably more challenging than judging the risk 
of bias. The tool includes an optional component to pre-
dict the direction of the bias for each domain, and over-
all. For some domains, the bias is most easily thought of 
as being towards or away from the null. For example, 
suspicion of selective non-reporting of statistically 
non-signiicant results would suggest bias against the 
null. However, for other domains (in particular con-
founding, selection bias and forms of measurement 
bias such as diferential misclassiication), the bias 
needs to be thought of as an increase or decrease in the 
efect estimate and not in relation to the null. For exam-
ple, confounding bias that decreases the efect estimate 
would be towards the null if the true risk ratio were 
greater than 1, and away from the null if the risk ratio 
were less than 1.
Discussion
We developed a tool for assessing risk of bias in the 
results of non-randomised studies of interventions 
that  addresses weaknesses in previously available 
approaches.4  Our approach builds on recent 
Table 2 | Interpretation of domain-level and overall risk of bias judgements in ROBINS-I*
Judgement Within each domain Across domains Criterion
Low risk of 
bias
The study is comparable to a well performed 
randomised trial with regard to this domain
The study is comparable to a well performed 
randomised trial
The study is judged to be at low risk of bias 
for all domains
Moderate 
risk of bias
The study is sound for a non-randomised study with 
regard to this domain but cannot be considered 
comparable to a well performed randomised trial
The study provides sound evidence for a non-
randomised study but cannot be considered 
comparable to a well performed randomised trial
The study is judged to be at low or moderate 
risk of bias for all domains
Serious risk 
of bias
The study has some important problems in this 
domain
The study has some important problems The study is judged to be at serious risk of 
bias in at least one domain, but not at critical 
risk of bias in any domain
Critical risk 
of bias
The study is too problematic in this domain to provide 
any useful evidence on the efects of intervention
The study is too problematic to provide any useful 
evidence and should not be included in any synthesis
The study is judged to be at critical risk of 
bias in at least one domain
No 
information
No information on which to base a judgement about 
risk of bias for this domain
No information on which to base a judgement about 
risk of bias
There is no clear indication that the study is at 
serious or critical risk of bias and there is a 
lack of information in one or more key domains 
of bias (a judgement is required for this)
*Also saved as supplementary table D.
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 developments in risk of bias assessment of randomised 
trials and diagnostic test accuracy studies.8 9 Key fea-
tures of ROBINS-I include speciication of the target 
trial and efect of interest, use of signalling questions to 
inform judgements of risk of bias, and assessments 
within seven bias domains.
The ROBINS-I tool was developed through consensus 
among a group that included both methodological 
experts and systematic review authors and editors, and 
was substantially revised based on extensive piloting 
and user feedback. It includes a structured approach to 
assessment of risk of bias due to confounding that 
starts at the review protocol stage. Use of ROBINS-I 
requires that review groups include members with sub-
stantial methodological expertise and familiarity with 
modern epidemiological thinking. We tried to make 
ROBINS-I as accessible and easy to use as possible, 
given the requirement for comprehensive risk of bias 
assessments that are applicable to a wide range of study 
designs and analyses. An illustrative assessment using 
ROBINS-I can be found at www.riskofbias.info; detailed 
guidance and further training materials will also be 
available.
ROBINS-I separates relatively factual answers to sig-
nalling questions from more subjective judgements 
about risk of bias. We hope that the explicit links 
between answers to signalling questions and risk of 
bias judgements will improve reliability of the 
domain-speciic and overall risk of bias assessments.14 
Nonetheless, we expect that the technical diiculty in 
making risk of bias judgements will limit reliability. 
Despite this, ROBINS-I provides a comprehensive and 
structured approach to assessing non-randomised 
studies of interventions. It should therefore facilitate 
debates and improve mutual understanding about the 
ways in which bias can inluence efects estimated in 
NRSI, and clarify reasons for disagreements about spe-
ciic risk of bias judgements. Note that the tool focuses 
speciically on bias and does not address problems 
related to imprecision of results, for example when sta-
tistical analyses fail to account for clustering or match-
ing of participants.
We developed the ROBINS-I tool primarily for use in 
the context of a systematic review. Broader potential 
uses include the assessment of funding applications 
and peer review of journal submissions. Furthermore, 
ROBINS-I may be used to guide researchers about issues 
to consider when designing a primary study to evaluate 
the efect(s) of an intervention.
Figure 1  summarises the process of assessing risk of 
bias using the tool in the context of a systematic review 
of NRSI. To draw conclusions about the extent to which 
observed intervention efects might be causal, the stud-
ies included in the review should be compared and con-
trasted so that their strengths and weaknesses can be 
considered jointly. Studies with diferent designs may 
present diferent types of bias, and “triangulation” of 
indings across these studies may provide assurance 
either that the biases are minimal or that they are real. 
Syntheses of indings across studies through meta-anal-
ysis must consider the risks of bias in the studies avail-
able. We recommend against including studies assessed 
as at “Critical risk” of bias in any meta-analysis, and 
advocate caution for studies assessed as at “Serious 
risk” of bias. Subgroup analyses (in which intervention 
efects are estimated separately according to risk of 
bias), meta-regression analyses, and sensitivity analy-
ses (excluding studies at higher risk of bias) might be 
considered, either within speciic bias domains or over-
all. Risk of bias assessments might alternatively be used 
as the basis for deriving adjustments for bias through 
prior distributions in Bayesian meta-analyses.15 16
The GRADE system for assessing conidence in esti-
mates of the efects of interventions currently assigns a 
starting rating of “Low certainty, conidence or quality” 
to non-randomised studies, a downgrading by default 
of two levels.17 ROBINS-I provides a thorough assess-
ment of risk of bias in relation to a hypothetical ran-
domised trial, and “Low risk” of bias corresponds to the 
risk of bias in a high quality randomised trial. This 
opens up the possibility of using the risk of bias assess-
ment, rather than the lack of randomisation per se, to 
determine the degree of downgrading of a study result, 
and means that results of NRSI and randomised trials 
could be synthesised if they are assessed to be at similar 
risks of bias. In general, however, we advocate analys-
ing these study designs separately and focusing on evi-
dence from NRSI when evidence from trials is not 
available.
Planned developments of ROBINS-I include further 
consideration of the extent to which it works for speciic 
types of NRSI, such as self-controlled designs, con-
trolled before-and-after studies, interrupted time series 
studies, and studies based on regression discontinuity 
and instrumental variable analyses. We also plan to 
develop interactive software to facilitate use of ROB-
INS-I. Furthermore, the discussions that led up to the 
tool will inform a reconsideration of the tool for ran-
domised trials, particularly in the four post-interven-
tion domains.8
The role of NRSI in informing treatment decisions 
remains controversial. Because randomised trials are 
expensive, time consuming, and may not relect real 
Stage I: Planning
Specify research question; list potential confounding domains and co-interventions
Stage II: Risk of bias assessment for speci	c result
Stage III: Overall risk of bias assessment
‘Triangulate’ across studies
For each study
Stage II-1:
Specify target trial
and eect of interest 
Stage II-2:
Select the
result to assess
Stage II-3:
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Fig 1 | Summary of the process of assessing risk of bias in a systematic review of 
non-randomised studies of interventions (NRSI)
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world experience with healthcare interventions, 
research funders are enthusiastic about the possible 
use of observational studies to provide evidence about 
the comparative efectiveness of diferent interven-
tions,18  and encourage use of large, routinely collected 
datasets assembled through data linkage.18  However, 
fear that evidence from NRSI may be biased, based on 
misleading results of some NRSI,19 20  has led to caution 
in their use in making judgements about eicacy. There 
is greater conidence in the capacity of NRSI to quantify 
uncommon adverse effects of interventions.21  We 
believe that evidence from NRSI should complement 
that from randomised trials, such as in providing evi-
dence about efects on rare and adverse outcomes and 
long term efects to be balanced against the outcomes 
more readily addressed in randomised trials.22
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Appendix: The seven domains of bias addressed in 
the ROBINS-I assessment tool
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